Ribozyme Pharmaceuticals, Incorporated

Sirna Therapeutics, Inc.

Jasenka Matulic-Adamic

Leonid Beigelman

Alexander Karpeisky

Nassim Usman

Alex Karpeisky

Francine E Wincott

Alex B Burgin

Amber Beaudry

Shawn Patrick Zinnen

Lech W Dudycz

Mark Reynolds

John Min

James A McSwiggen

Chandra Vargeese

David Sweedler

Thale Jarvis

Peter Haeberli

Anthony DiRenzo

Nilabh Chaudhary

Tod M Woolf

James D Thompson

Laurent Bellon

Christopher Shaffer

Michael Zwick

Lawrence Blatt

This invention features conjugates, compositions, methods of synthesis, and applications thereof, including folate derived conjugates of nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids and antisense nucleic acid molecules.

Conjugates and compositions for cellular delivery

This invention features permeability enhancer molecules, and methods, to increase membrane permeability of various molecules, such as nucleic acids, polynucleotides, oligonucleotides, enzymatic nucleic acid molecules, antisense nucleic acid molecules, 2-5A antisense chimeras, triplex forming oligonucleotides, decoy RNAS, dsRNAs, siRNAs, aptamers, or antisense nucleic acids containing nucleic acid cleaving chemical groups, peptides, polypeptides, proteins, carbohydrates, steroids, metals and small molecules, thereby facilitating cellular uptake of such molecules.

Compositions for the delivery of negatively charged molecules

The present invention relates to RNA molecules containing one or more non-nucleotide mimetics.

Non-nucleotide containing RNA

Novel xylo nucleoside or xylo nucleotide analogs, polynucleotides comprising xylo nucleotide substitution, processes for their synthesis and incorporation into polynucleotides.

Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides

This invention relates to novel chemically-modified nucleic acid molecules having specific formulae that exhibit increased resistance to nucleases and increased binding affinity to target nucleic acid molecules. The invention further relates to methods of modulating gene expression using the novel chemically modified nucleic acid molecules, and compositions and cells comprising said molecules.

Nucleic acid molecules with novel chemical compositions capable of modulating gene expression

Novel nucleotide triphosphates, methods of synthesis and process of incorporating these nucleotide triphosphates into oligonucleotides, and isolation of novel nucleic acid catalysts (e.g., ribozymes) are disclosed. Also, described are the use of novel enzymatic nucleic acid molecules to inhibit HER2/neu/ErbB2 gene expression and their applications in human therapy.

Oligoribonucleotides with enzymatic activity

An enzymatic nucleic acid molecule comprising a 5&prime;- and/or a 3&prime;-cap structure, wherein said structure is not a 5&prime;-5&prime;-linked inverted nucleotide or a 3&prime;-3&prime;-linked inverted nucleotide.

Enzymatic nucleic acids containing 5&prime;-and or 3&prime;-cap structures

Enzymatic nucleic acid molecule containing one or more non-nucleotide mimetics, and having activity to cleave an RNA or DNA molecule.

Non-nucleotide containing enzymatic nucleic acid

Synthetic ribonucleic acids with RNAse activity

Novel nucleoside triphosphates, methods of synthesis and process of incorporating these nucleoside triphosphates into oligonucleotides are disclosed.

Nucleoside triphosphates and their incorporation into oligonucleotides

Novel nucleotide triphosphates, methods of synthesis and process of incorporating these nucleotide triphosphates into oligonucleotides, and isolation of novel nucleic acid catalysts (e.g., ribozymes) are disclosed.

Growing community of inventors

Boulder, CO, United States of America

Jasenka Matulic-Adamic